Recent advances and challenges of cellular immunotherapies in lung cancer treatment [0.03%]
肺癌治疗中细胞免疫疗法的新进展和挑战
Chengfei Yang,Yue Liu,Ziqi Huang et al.
Chengfei Yang et al.
Lung cancer is a major malignant tumor with high morbidity and fatality rates. For many years, traditional treatments for lung cancer have struggled to achieve a favorable outlook and prognosis. It is crucial to identify and innovate novel ...
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases [0.03%]
膀胱癌亚型在不同微环境和转移灶中表现出有限的可塑性
Carina Bernardo,Subhayan Chattopadhyay,Natalie Andersson et al.
Carina Bernardo et al.
Background: Transcriptomic and genomic analyses of bladder cancer (BC) reveal a highly diverse disease stratified into molecular subtypes with distinct molecular features and biological behaviors. Intratumor heterogeneity...
Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial [0.03%]
allo-DN-T细胞预防高危AML患者移植后复发的I期临床研究
Guangyu Sun,Xingchi Chen,Tianzhong Pan et al.
Guangyu Sun et al.
Relapse remains a major challenge for high-risk acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). In our first-in-human Phase I trial (ChiCTR-1900022795), we have demonstrated th...
Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy [0.03%]
嵌合抗原受体工程细胞免疫治疗的现状、挑战与机遇
Yong Liu,Yifei Duan,Zefan Du et al.
Yong Liu et al.
Chimeric antigen receptor (CAR) engineered cellular immunotherapy offers the potential for precise targeting and elimination of tumor cells, providing a tailored approach to cancer treatment. CAR-T cells demonstrate significant anti-tumor a...
High cereblon expression in neuroendocrine cancer confers vulnerability to GSPT1 molecular glue degrader [0.03%]
神经内分泌癌中高表达的 cereblon 使其对 GSPT1 分子胶降解剂更易感
Jaewoo Park,Min Sung Joo,Myung Jun Kim et al.
Jaewoo Park et al.
Background: Recent advances in targeted therapies have introduced molecular glue degraders (MGDs) that leverage the cereblon (CRBN) E3 ubiquitin ligase to degrade the translation termination factor GSPT1. Understanding th...
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity [0.03%]
MIT抑制剂karonudib杀死卵巢癌细胞独立于铂敏感性
Rachel M Hurley,Jill M Wagner,Arun Kanakkanthara et al.
Rachel M Hurley et al.
The prognosis for women with ovarian cancer (OC) is particularly poor if resistance to platinum compounds, the mainstay of standard-of-care therapy, develops. Inhibitors of the Nudix hydrolase MuT Homolog 1 (MTH1) have previously been shown...
Rohit Thalla,Ryan Mack,Jorgena Kosti-Schwartz et al.
Rohit Thalla et al.
Myelodysplastic syndromes (MDS) is a heterogeneous group of pre-leukemic diseases characterized by peripheral blood cytopenia, morphologic dysplasia, and an increased risk of transformation to leukemia. MDS develop from genetically mutant c...
Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer [0.03%]
同源重组-DNA损伤反应缺陷增加胰腺癌的TMB和新生抗原负荷，但不会增加效应T细胞密度和克隆多样性
Mengyue Lei,Jessica Gai,Thomas J McPhaul et al.
Mengyue Lei et al.
Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to chemotherapy. However, PDAC with germline BRCA mutations, which lead to homologous recombination (HR) deficiency (HRD), demonstrated an increased sensitivity to platinum-based c...
Multi-omics analyses of the heterogenous immune microenvironment in triple-negative breast cancer implicate UQCRFS1 potentiates tumor progression [0.03%]
多组学分析揭示三阴性乳腺癌异质性免疫微环境中的UQCRFS1促进肿瘤进展
Yuhui Tang,Aiqi Xu,Zhongbiao Xu et al.
Yuhui Tang et al.
Background: Triple-negative breast cancer (TNBC) is commonly characterized by high-grade and aggressive features, resulting in an augmented likelihood of distant metastasis and inferior prognosis for patients. Tumor immun...
Correction: Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma [0.03%]
题目改正：赖氨酸特异性脱甲基酶1抑制作用增强蛋白酶体抑制剂的抑瘤作用并克服骨髓瘤的耐药性
Cecilia Bandini,Elisabetta Mereu,Tina Paradzik et al.
Cecilia Bandini et al.
Published Erratum
Experimental hematology & oncology. 2025 Jun 13;14(1):82. DOI:10.1186/s40164-025-00675-y 2025